Trading resumes today!Four times the size of the bull announcement
Yabunchem, a giant stock whose share price has quadrupled in three months, will resume trading on the first day of trading after the Lunar New Year holiday.The company again carried out a number of risk notes, pointing out that the stock price rise significantly higher than the company’s fundamental changes.In addition, the company also pointed out again that the company has no business contact or cooperation with Pfizer, and has not signed a cooperation agreement with Pfizer.Yabon Chemical co., LTD. (300261.SZ) announced on The evening of February 6th that the company’s shares were suspended from trading and resumed trading.The company’s shares will resume trading on Monday, February 7, 2022, according to the announcement.At the same time, Yamamoto chemical also carried out a number of risk tips.According to Arbon Chemical, “Calonic anhydride and its derivatives are processably available for the synthesis of Pfizer’s corona oral drug Parovide” as described in the company’s response to the letter of Concern disclosed on January 5, 2022, in which calonic anhydride and its derivatives refer to compounds rather than products specifically produced by the company.There is no certainty that calonic anhydride produced by the company and its derivatives can be used in the synthesis of Pfizer’s COVID-19 oral medication.Company with no business contacts and cooperation, Pfizer did not sign a cooperation agreement with Pfizer, fails to Pfizer GongYingKa dragon anhydride product, Pfizer also fails to provide any of the new champions league for oral administration front the quality standards of raw materials procurement, and customer refused to provide procurement company end-use kalong anhydride and its derivatives,The Company cannot determine whether the calonic anhydride products manufactured by the company meet Pfizer’s product requirements, nor has it conducted relevant technical verification to determine whether the calonic anhydride products manufactured by the Company are or can be used as Pfizer’s oral drug intermediates for COVID-19.Yamon Chemical also said that as of December 31, 2021, the company’s sales revenue of Caronic anhydride and its derivative products in 2021 is 27.073 million yuan (excluding tax), accounting for about 1% to 2% of the company’s total operating revenue in 2021, accounting for a relatively small proportion.It is not expected to have a material impact on the company’s 2021 results.As of December 31, 2021, the total amount of orders in hand for kalonic anhydride and its derivatives was 63,548,800 yuan (excluding tax).Yamamoto chemical also claimed that from November 1, 2021 to January 28, 2022, the company’s stock price increased by 432.55%, which was significantly higher than the change in the company’s fundamentals and did not match the company’s current fundamentals.Since November 1, 2021, the company’s stock price has increased significantly, the dynamic p/E level has been significantly higher than the industry average.According to the company’s annual earnings forecast, the growth rate of 2021 is not high.The above performance forecast shows that Yabon Chemical is expected to net profit attributable to shareholders of listed companies in 2021 of 180 million to 200 million yuan, an increase of 11.79% to 24.21% over the same period last year, net profit after deducting non-recurrent gains and losses of 142 million to 162 million yuan,Year-on-year growth of -1.54%-12.33%.The company’s non-recurring profit and loss in 2021 is about 38 million yuan, mainly due to the fair value change gain.In fact, Yabon chemical was suspended from trading on December 29, 2021 due to severe abnormal stock trading and resumed trading on Thursday, January 6, 2022. The shares fell 1.83% on the day of resumption and 19.99% the next day, but soon recovered their momentum.In the reply to the shenzhen Stock Exchange’s concern letter on the evening of January 5, 2022, Yabon Chemical responded to the fact that Wang Xinya, one of the actual controllers of the company, reduced his shareholding of 19 million shares of the company through a block transaction on November 30, 2021.Yabon chemical said that Wang xinya is the founding shareholder and one of the actual controllers of the company, and the company’s shares held by wang were acquired before the IPO. Since the company was listed on the Gem of shenzhen Stock Exchange on September 6, 2011, Wang xinya only reduced the company’s shares by 2 million shares in May 2015.On November 30, 2021, Wang Xinya reduced his holdings of 19 million shares of the company through bulk trading. The main reasons for this reduction were loan repayment, foreign investment and other personal capital needs.According to the data, Yabon Chemical frequently appeared on the dragon and Tiger list in the last three months, mostly from the sales department, but also from the organization.In fact, in recent months, despite the weak performance of the main index of the A-share market, the performance of individual stocks has been quite active. In addition to Yabunchem, there are also A number of stocks that have doubled, or even doubled several times.Statistics show that nearly 20 stocks on the Shanghai and Shenzhen stock exchanges have doubled since November 2021, and many have risen by more than 200 percent.Among them, Jiuan Medical treatment rose by more than 900%, Yaben chemical rose by more than 400%, and Tuoxin Pharmaceutical rose by more than 300%.If from the range of the maximum increase from the lowest point of view, the increase is more amazing, including jiuan medical rose more than 14 times.